Targeted Drug Delivery System for Pulmonary Fibrosis: Design and Development of Biomaterials

Abstract

Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, and leading to impaired lung function and respiratory failure. Although current treatments, such as pirfenidone and nintedanib, slow disease progression, they fail to completely halt or reverse fibrosis. Therefore, innovative therapeutic strategies are needed. Targeted drug delivery systems (TDDSs) are emerging as promising solutions. Biomaterials play critical roles in these systems by enhancing drug specificity, availability, and efficacy, while minimizing systemic toxicity. The most notable biomaterials include nanotechnology-based systems, including liposomes and polymeric nanoparticles, which facilitate drug penetration and slow release in fibrotic tissues. Hydrogels have three-dimensional structures providing controlled and sustained drug release at inflammation sites, and therefore are particularly valuable in PF treatment. Furthermore, biological carriers such as stem cells and extracellular vesicles have biocompatibility and anti-inflammatory effects that improve therapeutic outcomes. Despite the promising potential of these systems, clinical translation is hindered by several challenges, including immune clearance, stability of delivery platforms, and optimization of drug retention within diseased tissues. Interdisciplinary approaches integrating precision medicine with advancements in biomaterials may provide solutions opening new avenues for PF treatment. This review discusses current developments in targeted drug delivery for PF, emphasizing the importance of biomaterials, the mechanisms and barriers involved in pulmonary drug delivery, and future perspectives for overcoming current limitations. The ultimate goal is to improve patient outcomes by revolutionizing the approach to PF treatment through advanced drug delivery technologies.

Keywords

Biomaterials / nanoparticles / precision medicine / pulmonary fibrosis / targeted drug delivery

References

[1] Huang C, Ogawa R. The vascular involvement in soft tissue fibrosis-lessons learned from pathological scarring. Int J Mol Sci 2020; 21(7): 2542. [PMID: 32268503 DOI: 10.3390/ijms21072542]

[2] Savin IA, Zenkova MA, Sen’kova AV. Pulmonary fibrosis as a result of acute lung inflammation: molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. Int J Mol Sci 2022; 23(23): 14959. [PMID: 36499287 DOI: 10.3390/ijms232314959]

[3] Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res 2021; 22(1): 109. [PMID: 33865386 DOI: 10.1186/s12931-021-01711-1]

[4] Han SJ, Kim HH, Hyun D-G, Ji W, Choi C-M, et al. Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease. BMC Pulm Med 2024; 24(1): 136. [PMID: 38491506 DOI: 10.1186/s12890-024-02946-6]

[5] Chen Q, Liu P, Zhou H, Kong H, Xie W. An increased risk of lung cancer in combined pulmonary fibrosis and emphysema patients with usual interstitial pneumonia compared with patients with idiopathic pulmonary fibrosis alone: a systematic review and meta-analysis. Ther Adv Respir Dis 2021; 15: 17534666211017050. [PMID: 34011211 DOI: 10.1177/17534666211017050]

[6] Jang HJ, Park MS, Kim YS, Chang J, Lee JH, et al. The relationship between the severity of pulmonary fibrosis and the lung cancer stage. J Cancer 2021; 12(10): 2807-18. [PMID: 33854581 DOI: 10.7150/jca.51445]

[7] Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, et al. Idiopathic pulmonary fibrosis: molecular mechanisms and potential treatment approaches. Respir Investig 2020; 58(5): 320-35. [PMID: 32487481 DOI: 10.1016/j.resinv.2020.04.002]

[8] Gao D, Gao W, Zhai Z, Zhu W. Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis. Pharm Sci Adv 2024; 2: 100030. [DOI: 10.1016/j.pscia.2023.100030]

[9] Jaula H, Mattila L, Lappi-Blanco E, Salonen J, Vähänikkilä H, et al. Clinical, radiological and histopathological features of patients with familial pulmonary fibrosis. Respir Res 2024; 25(1): 239. [PMID: 38867203 DOI: 10.1186/s12931-024-02864-5]

[10] Palmucci S, Torrisi SE, Falsaperla D, Stefano A, Torcitto AG, et al. Assessment of lung cancer development in idiopathic pulmonary fibrosis patients using quantitative high-resolution computed tomography: a retrospective analysis. J Thorac Imaging 2020; 35(2): 115-22. [PMID: 31913257 DOI: 10.1097/RTI.0000000000000468]

[11] Tomassetti S, Poletti V, Ravaglia C, Sverzellati N, Piciucchi S, et al. Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. Eur Respir Rev 2022; 31(164): 210206. [PMID: 35418487 DOI: 10.1183/16000617.0206-2021]

[12] Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep 2021; 11(1): 8312. [PMID: 33859288 DOI: 10.1038/s41598-021-87747-1]

[13] Carobene L, Spina D, Disanto MG, Micheletto C, Mazzei MA, et al. Lung cancer and interstitial lung diseases: the lack of prognostic impact of lung cancer in IPF. Intern Emerg Med 2022; 17: 457-64. [PMID: 34524623 DOI: 10.1007/s11739-021-02833-6]

[14] Milman Krentsis I, Zheng Y, Rosen C, Shin SY, Blagdon C, et al. Lung cell transplantation for pulmonary fibrosis. Sci Adv 2024; 10(34): eadk2524. [PMID: 39178253 DOI: 10.1126/sciadv.adk2524]

[15] Kara S, Mogulkoc N, Kirkil G, Cetinkaya E, Ozbudak O, et al. Lung cancer in patients with pulmonary fibrosis: characteristics features and prognosis. Sarcoidosis Vasc Diffuse Lung Dis 2024; 41(4): e2024050. [PMID: 39655590 DOI: 10.36141/svdld.v41i4.15675]

[16] Marconi GD, Fonticoli L, Rajan TS, Pierdomenico SD, Trubiani O, et al. Epithelial-mesenchymal transition (EMT): the type-2 EMT in wound healing, tissue regeneration and organ fibrosis. Cells 2021; 10(7): 1587. [PMID: 34201858 DOI: 10.3390/cells10071587]

[17] Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112(12): 1776-84. [PMID: 14679171 DOI: 10.1172/JCI20530]

[18] Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017; 232(12): 3261-72. [PMID: 28079253 DOI: 10.1002/jcp.25797]

[19] Ren L-L, Li X-J, Duan T-T, Li Z-H, Yang J-Z, et al. Transforming growth factor-β signaling: from tissue fibrosis to therapeutic opportunities. Chem Biol Interact 2023; 369: 110289. [PMID: 36455676 DOI: 10.1016/j.cbi.2022.110289]

[20] Ma H, Liu S, Li S, Xia Y. Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis. Front Pharmacol 2022; 13: 918771. [PMID: 35721111 DOI: 10.3389/fphar.2022.918771]

[21] Wang Y, Jiao L, Qiang C, Chen C, Shen Z, et al. The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms. Biomed Pharmacother 2024; 171: 116116. [PMID: 38181715 DOI: 10.1016/j.biopha.2023.116116]

[22] Rana PS, Soler DC, Kort J, Driscoll JJ. Targeting TGF-β signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction. Front Cell Dev Biol 2022; 10: 1059715. [PMID: 36578789 DOI: 10.3389/fcell.2022.1059715]

[23] Huang C-Y, Chung C-L, Hu T-H, Chen J-J, Liu P-F, et al. Recent progress in TGF-β inhibitors for cancer therapy. Biomed Pharmacother 2021; 134: 111046. [PMID: 33341049 DOI: 10.1016/j.biopha.2020.111046]

[24] Bernstein ZJ, Shenoy A, Chen A, Heller NM, Spangler JB . Engineering the IL-4/IL-13 axis for targeted immune modulation. Immunol Rev 2023; 320(1): 29-57. [PMID: 37283511 DOI: 10.1111/imr.13230]

[25] Xu Y, Lan P, Wang T. The role of immune cells in the pathogenesis of idiopathic pulmonary fibrosis. Medicina 2023; 59(11): 1984. [PMID: 38004032 DOI: 10.3390/medicina59111984]

[26] Shi Z, Zhou M, Zhai J, Sun J, Wang X. Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis. Archiv Pharm 2024; 357(10): e2400192. [PMID: 38961537 DOI: 10.1002/ardp.202400192]

[27] Burgoyne RA, Fisher AJ, Borthwick LA. The role of epithelial damage in the pulmonary immune response. Cells 2021; 10(10): 2763. [PMID: 34685744 DOI: 10.3390/cells10102763]

[28] Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med 2021; 21(1): 411. [PMID: 34895203 DOI: 10.1186/s12890-021-01783-1]

[29] Man RK, Gogikar A, Nanda A, Janga LSN, Sambe HG, et al. A comparison of the effectiveness of nintedanib and pirfenidone in treating idiopathic pulmonary fibrosis: a systematic review. Cureus 2024; 16(2): e54268. [PMID: 38500898 DOI: 10.7759/cureus.54268]

[30] Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci 2023; 24(9): 7849. [PMID: 37175556 DOI: 10.3390/ijms24097849]

[31] Arshad MS, Khalid W, Ahmad RS, Khan MK, Ahmad MH, et al. Functional foods and human health: an overview. In: Arshad MS, Ahmad MH, editors. Functional foods phytochem health promoting potential. Rijeka: IntechOpen; 2021. pp. 3. [DOI: 10.5772/intechopen.99000]

[32] Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 2020; 62(4): 413-22. [PMID: 31967851 DOI: 10.1165/rcmb.2019-0328TR]

[33] Sgalla G, Comes A, Richeldi L. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert Opin Drug Saf 2021; 20(9): 1035-48. [PMID: 33881959 DOI: 10.1080/14740338.2021.1921143]

[34] Tsyplakova N, Ismailos G, Karalis VD. Optimising pirfenidone dosage regimens in idiopathic pulmonary fibrosis: toward a guide for personalised treatment. Xenobiotica 2025; 55: 25-37. PMID: 39764686 DOI: 10.1080/00498254.2025.2450440]

[35] Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, et al. Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc 2021; 18(7): 1121-8. [PMID: 33465323 DOI: 10.1513/AnnalsATS.202007-901OC]

[36] Serra López-Matencio JM, Gómez M, Vicente-Rabaneda EF, González-Gay MA, Ancochea J, et al. Pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of COVID-19 pandemic. Pharmaceuticals 2021; 14(8): 819. [PMID: 34451916 DOI: 10.3390/ph14080819]

[37] Thakkar D, Singh S, Wairkar S. Advanced delivery strategies of nintedanib for lung disorders and beyond: a comprehensive review. AAPS PharmSciTech 2024; 25(6): 150. [PMID: 38954161 DOI: 10.1208/s12249-024-02869-9]

[38] Gibb AA, Lazaropoulos MP, Elrod JW. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ Res 2020; 127(3): 427-47. [PMID: 32673537 DOI: 10.1161/CIRCRESAHA.120.316958]

[39] Hettiarachchi SU, Li Y-H, Roy J, Zhang F, Puchulu-Campanella E, et al. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models. Sci Transl Med 2020; 12(567): eaay3724. [PMID: 33115948 DOI: 10.1126/scitranslmed.aay3724]

[40] Trachalaki A, Irfan M, Wells AU. Pharmacological management of idiopathic pulmonary fibrosis: current and emerging options. Expert Opin Pharmacother 2021; 22(2): 191-204. [PMID: 32993388 DOI: 10.1080/14656566.2020.1822326]

[41] Singh S, Wairkar S. Revolutionizing the treatment of idiopathic pulmonary fibrosis: from conventional therapies to advanced drug delivery systems. AAPS PharmSciTech 2024; 25(4): 78. [PMID: 38589751 DOI: 10.1208/s12249-024-02793-y]

[42] MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology 2021; 26(6): 532-51. [PMID: 33893708 DOI: 10.1111/resp.14041]

[43] Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, et al. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals 2021; 14(8): 807. [PMID: 34451904 DOI: 10.3390/ph14080807]

[44] Iwanami Y, Ebihara K, Nakao K, Sato N, Miyagi M, et al. Benefits of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis receiving antifibrotic drug treatment. J Clin Med 2022; 11(18): 5336. [PMID: 36142983 DOI: 10.3390/jcm11185336]

[45] Chianese M, Screm G, Salton F, Confalonieri P, Trotta L, et al. Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows. Pharmaceuticals 2024; 17(6): 709. [PMID: 38931376 DOI: 10.3390/ph17060709]

[46] Yogaratnam D, Carey KM, Coppenrath V, Dawson A, LaMothe AB, et al. Side effects of drugs that act on the respiratory tract. Side Eff Drugs Annu 2023; 45: 147-60. [DOI: 10.1016/bs.seda.2023.09.008]

[47] Grześk G, Woźniak-Wiśniewska A, Błażejewski J, Górny B, Wołowiec Ł, et al. The interactions of nintedanib and oral anticoagulants-molecular mechanisms and clinical implications. Int J Mol Sci 2020; 22(1): 282. [PMID: 33396592 DOI: 10.3390/ijms22010282]

[48] Peixoto de Miranda ÉJF, Takahashi T, Iwamoto F, Yamashiro S, Samano E, et al. Drug-Drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms. Clin Appl Thromb Hemost 2020; 26: 1076029620936325. [PMID: 32862668 DOI: 10.1177/1076029620936325]

[49] Cignarella A, Fadini GP, Bolego C, Trevisi L, Boscaro C, et al. Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovasc Res 2022; 118(4): 988-1003. [PMID: 33739385 DOI: 10.1093/cvr/cvab096]

[50] Cilli A, Uzer F, Sevinç C, Coşkun F, Ursavaş A, et al. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2021; 71: 102099. [PMID: 34793978 DOI: 10.1016/j.pupt.2021.102099]

[51] Ma H, Wu X, Li Y, Xia Y. Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Front Pharmacol 2022; 13: 963054. [PMID: 35935869 DOI: 10.3389/fphar.2022.963054]

[52] Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther 2021; 222: 107798. [PMID: 33359599 DOI: 10.1016/j.pharmthera.2020.107798]

[53] Nagar L, Saini A, Singh SK, Gupta G, MacLoughlin R, et al. Recent trends and applications of nanostructure-based drug delivery in alleviating pulmonary fibrosis. Eur Poly J 2024; 220: 113467. [DOI: 10.1016/j.eurpolymj.2024.113467]

[54] Ghosh S, Chowdhury SR, Rahaman M, Basu B, Prajapati B. Revolutionizing influenza treatment: a deep dive into targeted drug delivery systems. Curr Pharm Biotechnol 2024. [PMID: 39440775 DOI: 10.2174/0113892010326373241012061547]

[55] Gonzalez AV, Silvestri GA, Korevaar DA, Gesthalter YB, Almeida ND, et al. Assessment of advanced diagnostic bronchoscopy outcomes for peripheral lung lesions: a delphi consensus definition of diagnostic yield and recommendations for patient-centered study designs. An official American thoracic society/American college of chest physicians research statement. Am J Respir Crit Care Med 2024; 209(6): 634-46. [PMID: 38394646 DOI: 10.1164/rccm.202401-0192ST]

[56] Gencer A, Duraloglu C, Ozbay S, Ciftci TT, Yabanoglu-Ciftci S, et al. Recent advances in treatment of lung cancer: nanoparticle-based drug and siRNA delivery systems. Curr Drug Deliv 2021; 18(2): 103-20. [PMID: 32748745 DOI: 10.2174/1567201817999200730211718]

[57] Sparling K, Butler DC. Oral corticosteroids for skin disease in the older population: minimizing potential adverse effects. Drugs Aging 2024; 41(10): 795-808. [PMID: 39285122 DOI: 10.1007/s40266-024-01143-8]

[58] Miravitlles M, Auladell-Rispau A, Monteagudo M, Vázquez-Niebla JC, Mohammed J, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev 2021; 30(160): 210075. [PMID: 34168063 DOI: 10.1183/16000617.0075-2021]

[59] Galicia-Moreno M, Monroy-Ramirez HC, Caloca-Camarena F, Arceo-Orozco S, Muriel P, et al. A new opportunity for N-acetylcysteine. an outline of its classic antioxidant effects and its pharmacological potential as an epigenetic modulator in liver diseases treatment. Naunyn Schmiedebergs Arch Pharmacol 2024; 398: 2365-2386. [PMID: 39436429 DOI: 10.1007/s00210-024-03539-0]

[60] Wong KK, Lee SWH, Kua KP. N-acetylcysteine as adjuvant therapy for COVID-19 - a perspective on the current state of the evidence. J Inflamm Res 2021; 14: 2993-3013. [PMID: 34262324 DOI: 10.2147/JIR.S306849]

[61] Xie L, Xie D, Du Z, Xue S, Wang K, et al. A novel therapeutic outlook: classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer. Int J Oncol 2024; 64(4): 38. [PMID: 38391039 DOI: 10.3892/ijo.2024.5626]

[62] Borandeh S, van Bochove B, Teotia A, Seppälä J. Polymeric drug delivery systems by additive manufacturing. Adv Drug Deliv Rev 2021; 173: 349-73. [PMID: 33831477 DOI: 10.1016/j.addr.2021.03.022]

[63] Hariharan A, Tran SD. Localized drug delivery systems: an update on treatment options for head and neck squamous cell carcinomas. Pharmaceutics 2023; 15(7): 1844. [PMID: 37514031 DOI: 10.3390/pharmaceutics15071844]

[64] Beck H, Thaler T, Meibom D, Meininghaus M, Jörißen H, et al. Potent and selective human prostaglandin F (FP) receptor antagonist (BAY-6672) for the treatment of idiopathic pulmonary fibrosis (IPF). J Med Chem 2020; 63(20): 11639-62. [PMID: 32969660 DOI: 10.1021/acs.jmedchem.0c00834]

[65] Kaur R, Shaikh TB, Priya Sripadi H, Kuncha M, Vijaya Sarathi UVR, et al. Nintedanib solid lipid nanoparticles improve oral bioavailability and ameliorate pulmonary fibrosis in vitro and in vivo models. Int J Pharm 2024; 649: 123644. [PMID: 38040396 DOI: 10.1016/j.ijpharm.2023.123644]

[66] Westra N, Touw D, Lub-de Hooge M, Kosterink J, Oude Munnink T. Pharmacokinetic boosting of kinase inhibitors. Pharmaceutics 2023; 15(4): 1149. [PMID: 37111635 DOI: 10.3390/pharmaceutics15041149]

[67] Deng Z, Kalin GT, Shi D, Kalinichenko VV. Nanoparticle delivery systems with cell-specific targeting for pulmonary diseases. Am J Respir Cell Mol Biol 2021; 64(3): 292-307. [PMID: 33095997 DOI: 10.1165/rcmb.2020-0306TR]

[68] Pramanik S, Mohanto S, Manne R, Rajendran RR, Deepak A, et al. Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases. Mol Pharm 2021; 18(10): 3671-718. [PMID: 34491754 DOI: 10.1021/acs.molpharmaceut.1c00491]

[69] Tian H, Zhang T, Qin S, Huang Z, Zhou L, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol 2022; 15(1): 132. [PMID: 36096856 DOI: 10.1186/s13045-022-01320-5]

[70] Sun R, Chen Y, Pei Y, Wang W, Zhu Z, et al. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. Heliyon 2024; 10(18): e38165. [DOI: 10.1016/j.heliyon.2024.e38165]

[71] Liang T, Gao J, Feng R, Zheng Y, Tian K, et al. Recent progress in poly (Lactic-Co-Glycolic Acid)-based biodegradable drug delivery carriers for pain management. Processes 2024; 12(7): 1372. [DOI: 10.3390/pr12071372]

[72] Arber Raviv S, Alyan M, Egorov E, Zano A, Harush MY, et al. Lung targeted liposomes for treating ARDS. J Control Release 2022; 346: 421-33. [PMID: 35358610 DOI: 10.1016/j.jconrel.2022.03.028]

[73] Yathavan B, Ellis A, Jedrzkiewicz J, Subrahmanyam N, Khurana N, et al. Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis. J Control Release 2023; 360: 274-84. [PMID: 37353160 DOI: 10.1016/j.jconrel.2023.06.030]

[74] Sakthi Devi R, Girigoswami A, Siddharth M, Girigoswami K. Applications of gold and silver nanoparticles in theranostics. Appl Biochem Biotechnol 2022; 194(9): 4187-219. [PMID: 35551613 DOI: 10.1007/s12010-022-03963-z]

[75] Gupta N, Malviya R. Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer. Biochim Biophys Acta Rev Cancer 2021; 1875(2): 188532. [PMID: 33667572 DOI: 10.1016/j.bbcan.2021.188532]

[76] Rahim MA, Jan N, Khan S, Shah H, Madni A, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers 2021; 13(4): 670. [PMID: 33562376 DOI: 10.3390/cancers13040670]

[77] Ye J, Pei W, Zhu J, Li P, Liu H, et al. Research progress on gel-based nanocomposites for diagnosis and treatment of respiratory diseases. Mater Adv 2023; 4: 5431-52. [DOI: 10.1039/D3MA00129F]

[78] Gutierrez AM, Frazar EM, X Klaus MV, Paul P, Hilt JZ. Hydrogels and hydrogel nanocomposites: enhancing healthcare through human and environmental treatment. Adv Healthc Mater 2022; 11(7): 2101820. [PMID: 34811960 DOI: 10.1002/adhm.202101820]

[79] Cao H, Wang M, Ding J, Lin Y. Hydrogels: a promising therapeutic platform for inflammatory skin diseases treatment. J Mater Chemi B 2024; 12(33): 8007-32. [DOI: 10.1039/D4TB00887A]

[80] He S, Gui J, Xiong K, Chen M, Gao H, et al. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnol 2022; 20(1): 101. [DOI: 10.1186/s12951-022-01307-x]

[81] Fragni D. Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model. 2022. [DOI: 10.25434/fragni-debora_phd2022]

[82] Davila JGF. Investigating extracellular matrix-derived hydrogels from the lungs of patients with idiopathic pulmonary fibrosis as an in vitro disease model. George Mason University; 2024.

[83] Anggelia MR, Cheng HY, Lin CH. Thermosensitive hydrogels as targeted and controlled drug delivery systems: potential applications in transplantation. Macromol Biosci 2024; 24(10): 2400064. [PMID: 38991045 DOI: 10.1002/mabi.202400064]

[84] Alaghawani NA, Alkhatib H, Elmancy L, Daou A. Harmonizing innovations: an in-depth comparative review on the formulation, applications, and future perspectives of aerogels and hydrogels in pharmaceutical sciences. Gels 2024; 10(10): 663. [PMID: 39451316 DOI: 10.3390/gels10100663]

[85] Agarwal T, Kazemi S, Costantini M, Perfeito F, Correia CR, et al. Oxygen releasing materials: towards addressing the hypoxia-related issues in tissue engineering. Mater Sci Eng C Mater Biol Appl 2021; 122: 111896. [PMID: 33641899 DOI: 10.1016/j.msec.2021.111896]

[86] He Y, Chang Q, Lu F. Oxygen-releasing biomaterials for chronic wounds breathing: from theoretical mechanism to application prospect. Mater Today Bio 2023; 20: 100687. [PMID: 37334187 DOI: 10.1016/j.mtbio.2023.100687]

[87] Kang W, Xu Z, Lu H, Liu S, Li J, et al. Advances in biomimetic nanomaterial delivery systems: harnessing nature’s inspiration for targeted drug delivery. J Mater Chem B 2024; 12(29): 7001-19. [DOI: 10.1039/D4TB00565A]

[88] Wang J, Zhu M, Nie G. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev 2021; 178: 113974. [PMID: 34530015 DOI: 10.1016/j.addr.2021.113974]

[89] Ke W, Afonin KA. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Adv Drug Deliv Re v2021; 176: 113835. [PMID: 34144087 DOI: 10.1016/j.addr.2021.113835]

[90] Almeida AF, Miranda MS, Reis RL, Gomes ME, Rodrigues MT. Using hybrid nanoplatforms to combine traditional anti-inflammatory drug delivery with RNA-based therapeutics for macrophage reprograming. Int J Mol Sci 2024; 25(19): 10693. [PMID: 39409023 DOI: 10.3390/ijms251910693]

[91] Lan M, Lu W, Zou T, Li L, Liu F, et al. Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. Cell Mol Life Sci 2021; 78: 2105-29. [PMID: 33386887 DOI: 10.1007/s00018-020-03696-4]

[92] Mirra D, Cione E, Spaziano G, Esposito R, Sorgenti M, et al. Circulating microRNAs expression profile in lung inflammation: a preliminary study. J Clin Med 2022; 11(18): 5446. [PMID: 36143090 DOI: 10.3390/jcm11185446]

[93] Raza F, Zafar H, Zhang S, Kamal Z, Su J, et al. Recent advances in cell membrane-derived biomimetic nanotechnology for cancer immunotherapy. Adv Healthc Mater 2021; 10(6): 2002081. [PMID: 33586322 DOI: 10.1002/adhm.202002081]

[94] Dhas N, García MC, Kudarha R, Pandey A, Nikam AN, et al. Advancements in cell membrane camouflaged nanoparticles: a bioinspired platform for cancer therapy. J Control Release 2022; 346: 71-97. [PMID: 35439581 DOI: 10.1016/j.jconrel.2022.04.019]

[95] Wang C, Wu S. Research update on cell membrane camouflaged nanoparticles for cancer therapy. Front Bioeng Biotechnol 2022; 10: 944518. [PMID: 35992357 DOI: 10.3389/fbioe.2022.944518]

[96] Wu Y, Wan S, Yang S, Hu H, Zhang C, et al. Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. J Nanobiotechnology 2022; 20(1): 542. [PMID: 36575429 DOI: 10.1186/s12951-022-01746-6]

[97] Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther 2022; 39: 102915. [PMID: 35597441 DOI: 10.1016/j.pdpdt.2022.102915]

[98] Zi Y, Yang K, He J, Wu Z, Liu J, et al. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev 2022; 188: 114449. [PMID: 35835353 DOI: 10.1016/j.addr.2022.114449]

[99] Sebak AA, El-Shenawy BM, El-Safy S, El-Shazly M. From passive targeting to personalized nanomedicine: multidimensional insights on nanoparticles’ interaction with the tumor microenvironment. Curr Pharm Biotechnol 2021; 22(11): 1444-65. [PMID: 33308126 DOI: 10.2174/1389201021666201211103856]

[100] Slack R, Macdonald S, Roper J, Jenkins R, Hatley R. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov 2022; 21(1): 60-78. [DOI: 10.1038/s41573-021-00284-4]

[101] Ni Y, Huang M, Chen S, Wang S, Chen J. Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications: integrins and NAFLD-associated liver diseases. Acta Biochim Biophys Sin 2024; 56(11): 1573-83. [DOI: 10.3724/abbs.2024149]

[102] Nikolopoulos VK, Augustine R, Camci-Unal G. Harnessing the potential of oxygen-generating materials and their utilization in organ-specific delivery of oxygen. Biomater Sci 2023; 11(5): 1567-88. [DOI: 10.1039/D2BM01329K]

[103] Maurya R, Vikal A, Patel P, Narang RK, Kurmi BD. Enhancing oral drug absorption: overcoming physiological and pharmaceutical barriers for improved bioavailability. AAPS PharmSciTech 2024; 25(7): 228. [PMID: 39354282 DOI: 10.1208/s12249-024-02940-5]

[104] Sodha SJ, Patel M, Nagarkar R, Mohammed IA, Patel H. Translation of pulmonary protein therapy from bench to bedside: addressing the bioavailability challenges. J Drug Deliv Sci Technol 2021; 64: 102664. [DOI: 10.1016/j.jddst.2021.102664]

[105] Chen Y-C, Gad SF, Chobisa D, Li Y, Yeo Y. Local drug delivery systems for inflammatory diseases: status quo, challenges, and opportunities. J Control Release 2021; 330: 438-60. [PMID: 33352244 DOI: 10.1016/j.jconrel.2020.12.025]

[106] Boboltz A, Kumar S, Duncan GA. Inhaled drug delivery for the targeted treatment of asthma. Adv Drug Deliv Rev 2023; 198: 114858. [PMID: 37178928 DOI: 10.1016/j.addr.2023.114858]

[107] Soni SS, D’Elia AM, Alsasa A, Cho S, Tylek T, et al. Sustained release of drug-loaded nanoparticles from injectable hydrogels enables long-term control of macrophage phenotype. Biomater Sci 2022; 10(24): 6951-67. [DOI: 10.1039/D2BM01113A]

[108] Kong Y, Shi W, Zheng L, Zhang D, Jiang X, et al. In situ delivery of a curcumin-loaded dynamic hydrogel for the treatment of chronic peripheral neuropathy. J Control Release 2023; 357: 319-32. [PMID: 37028453 DOI: 10.1016/j.jconrel.2023.04.002]

[109] He A, He L, Chen T, Li X, Cao C. Biomechanical properties and cellular responses in pulmonary fibrosis. Bioengineering 2024; 11(8): 747. [PMID: 39199705 DOI: 10.3390/bioengineering11080747]

[110] Saleh KS, Hewawasam R, Šerbedžija P, Blomberg R, Noreldeen SE, et al. Engineering hybrid-hydrogels comprised of healthy or diseased decellularized extracellular matrix to study pulmonary fibrosis. Cell Mol Bioeng 2022; 15(5): 505-19. [PMID: 36444345 DOI: 10.1007/s12195-022-00726-y]

[111] Batasheva S, Kotova S, Frolova A, Fakhrullin R. Atomic force microscopy for characterization of decellularized extracellular matrix (dECM) based materials. Sci Technol Adv Mater 2024; 25(1): 2421739. [PMID: 39559530 DOI: 10.1080/14686996.2024.2421739]

[112] Randhawa A, Dutta SD, Ganguly K, Patil TV, Lim KT. Manufacturing 3D biomimetic tissue: a strategy involving the integration of electrospun nanofibers with a 3D-printed framework for enhanced tissue regeneration. Small 2024; 20(27): e2309269. [PMID: 38308170 DOI: 10.1002/smll.202309269]

[113] Cojocaru E, Petriş OR, Cojocaru C. Nanoparticle-based drug delivery systems in inhaled therapy: improving respiratory medicine. Pharmaceuticals 2024; 17(8): 1059. [PMID: 39204164 DOI: 10.3390/ph17081059]

[114] Yong J, Shu H, Zhang X, Yang K, Luo G, et al. Natural products-based inhaled formulations for treating pulmonary diseases. Int J Nanomedicine 2024; 19: 1723-48. [PMID: 38414528 DOI: 10.2147/IJN.S451206]

[115] Ghumman M, Dhamecha D, Gonsalves A, Fortier L, Sorkhdini P, et al. Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment. Eur J Pharm Biopharm 2021; 164: 1-12. [PMID: 33882301 DOI: 10.1016/j.ejpb.2021.03.017]

[116] Lee WT, Lee H, Kim J, Jung Y, Choi E, et al. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioact Maters 2024; 33: 262-78. [PMID: 38076650 DOI: 10.1016/j.bioactmat.2023.11.005]

[117] Park S, Park J, Nahm J, Kim G, Cho Y, et al. Systemic delivery of nintedanib using PLGA-based discoidal polymeric particles for idiopathic pulmonary fibrosis treatment. Mater Today Chem 2022; 26: 101181. [DOI: 10.1016/j.mtchem.2022.101181]

[118] Vallet-Regí M, Schüth F, Lozano D, Colilla M, Manzano M. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev 2022; 51(13): 5365-451. [DOI: 10.1039/D1CS00659B]

[119] Wang Y, Gou K, Guo X, Ke J, Li S, et al. Advances in regulating physicochemical properties of mesoporous silica nanocarriers to overcome biological barriers. Acta Biomater 2021; 123: 72-92. [PMID: 33454385 DOI: 10.1016/j.actbio.2021.01.005]

[120] Dhoundiyal S, Alam MA, Kaur A, Sharma S. Nanomedicines: impactful approaches for targeting pulmonary diseases. Pharm Nanotechnol 2024; 12(1): 14-31. [PMID: 37231722 DOI: 10.2174/2211738511666230525151106]

[121] Jain N, Shashi Bhushan B, Natarajan M, Mehta R, Saini DK, et al. Advanced 3D in vitro lung fibrosis models: contemporary status, clinical uptake, and prospective outlooks. ACS Biomater Sci Eng 2024; 10(3): 1235-61. [PMID: 38335198 DOI: 10.1021/acsbiomaterials.3c01499]

[122] Machahua C, Vicens-Zygmunt V, Ríos-Martín J, Llatjós R, Escobar-Campuzano I, et al. Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis. Exp Lung Res 2022; 48(3): 126-36. [PMID: 35594338 DOI: 10.1080/01902148.2022.2067265]

[123] Antar SA, Ashour NA, Marawan ME, Al-Karmalawy AA. Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int J Mol Sci 2023; 24(4): 4004. [PMID: 36835428 DOI: 10.3390/ijms24044004]

[124] Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic pulmonary fibrosis: an update on pathogenesis. Front Pharmacol 2022; 12: 797292. [PMID: 35126134 DOI: 10.3389/fphar.2021.797292]

[125] D’Agnillo F, Walters K-A, Xiao Y, Sheng Z-M, Scherler K, et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci Transl Med 2021; 13(620): eabj7790. [PMID: 34648357 DOI: 10.1126/scitranslmed.abj7790]

[126] Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol 2021; 21(11): 704-17. [PMID: 33911232 DOI: 10.1038/s41577-021-00540-z]

[127] Keshavan S, Bannuscher A, Drasler B, Barosova H, Petri-Fink A, et al. Comparing species-different responses in pulmonary fibrosis research: current understanding of in vitro lung cell models and nanomaterials. Eur J Pharm Sci 2023; 183: 106387. [PMID: 36652970 DOI: 10.1016/j.ejps.2023.106387]

[128] Yuan K, Du X, Dong L, Pan J, Xue W. Modelling the tumor microenvironment in vitro in prostate cancer: current and future perspectives. View 2024; 5(5): 20240074. [DOI: 10.1002/VIW.20240074]

[129] Vernerey FJ, Lalitha Sridhar S, Muralidharan A, Bryant SJ. Mechanics of 3D cell-hydrogel interactions: experiments, models, and mechanisms. Cheml Rev 2021; 121(18): 11085-148. [PMID: 34473466 DOI: 10.1021/acs.chemrev.1c00046]

[130] Solbu AA, Caballero D, Damigos S, Kundu SC, Reis RL, et al. Assessing cell migration in hydrogels: an overview of relevant materials and methods. Mater Today Bio 2023; 18: 100537.

[131] Zhao T, Zhou Z-r, Wan H-q, Feng T, Hu X-h, et al. Otilonium bromide ameliorates pulmonary fibrosis in mice through activating phosphatase PPM1A. Acta Pharmacol Sin 2024; 46: 107-121. [DOI: 10.1038/s41401-024-01368-8]

[132] Li Y, Yin H, Yuan H, Wang E, Wang C, et al. IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN/AKT/ERK pathway. BMC Pulm Med 2024; 24(1): 443. [PMID: 39261827 DOI: 10.1186/s12890-024-03260-x]

[133] Jani K, Kaushal N. Clinical translation of PLGA nanoparticles into market - from benchside to breakthrough therapy. In: Poly (lactic-co-glycolic acid)(PLGA) nanoparticles for drug delivery. Elsevier; 2023. pp. 433-56. [DOI: 10.1016/B978-0-323-91215-0.00013-3]

[134] Recchiuti A, Mattoscio D, Isopi E. Roles, actions, and therapeutic potential of specialized pro-resolving lipid mediators for the treatment of inflammation in cystic fibrosis. Front Pharmacol 2019; 10: 252. [PMID: 31001110 DOI: 10.3389/fphar.2019.00252]

[135] Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58(9-10): 1030-60. [PMID: 17010473 DOI: 10.1016/j.addr.2006.07.012]

[136] Kole E, Jadhav K, Shirsath N, Dudhe P, Verma RK, et al. Nanotherapeutics for pulmonary drug delivery: an emerging approach to overcome respiratory diseases. J Drug Deliv Sci Technol 2023; 81: 104261. [DOI: 10.1016/j.jddst.2023.104261]

[137] Horalskyi L, Ragulya M, Glukhova N, Sokulskiy I, Kolesnik N, et al. Morphology and specifics of morphometry of lungs and myocardium of heart ventricles of cattle, sheep and horses. Regul Mech Biosyst 2022; 13(1): 53-9. [DOI: 10.15421/022207]

[138] Esquer C, Echeagaray O, Firouzi F, Savko C, Shain G, et al. Fundamentals of vaping-associated pulmonary injury leading to severe respiratory distress. Life Sci Alliance 2022; 5(2): e202101246. [PMID: 34810278 DOI: 10.26508/lsa.202101246]

[139] Khlebtsov NG, Dykman LA, Khlebtsov BN. Synthesis and plasmonic tuning of gold and gold-silver nanoparticles. Russ Chem Rev 2022; 91(10): RCR5058. [DOI: 10.57634/RCR5058]

[140] Fröhlich E. Replacement strategies for animal studies in inhalation testing. Sci 2021; 3(4): 45. [DOI: 10.3390/sci3040045]

[141] De Silva M. Gross and microscopic morphological anatomical study of the guinea pig (Cavia porcellus) and the capybara (Hydrochoerus hydrochaeris), aimed at the preparation of a comparative anatomical atlas of the different systems. 2022.

[142] Larcombe AN, Papini MG, Chivers EK, Berry LJ, Lucas RM, et al. Mouse lung structure and function after long-term exposure to an atmospheric carbon dioxide level predicted by climate change modeling. Environ Health Perspect 2021; 129(1): 017001. [PMID: 33439053 DOI: 10.1289/EHP7305]

[143] Uluer ET, Pekmezci MY, Epaud R, Ozbilgin MK. Histological characteristics of the upper respiratory tract: continuum with lower respiratory tract. In: Yüksel H, Yilmaz O, Bayar Muluk N, Myer CM, editors. Pediatric airway diseases. Comprehensive ENT. Springer; 2025. pp. 17-32. [DOI: 10.1007/978-3-031-74853-0_2]

[144] Dong J, Yang Y, Zhu Y. Recent advances in the understanding of alveolar flow. Biomicrofluidics 2022; 16(2): 021502. [PMID: 35464135 DOI: 10.1063/5.0084415]

[145] Gustafsson JK, Hansson GC. Immune regulation of goblet cell and mucus functions in health and disease. Annu Rev Immunol 2025. [PMID: 39752567 DOI: 10.1146/annurev-immunol-101721-065224]

[146] Dudala SS, Venkateswarulu T, Kancharla SC, Kodali VP, Babu DJ. A review on importance of bioactive compounds of medicinal plants in treating idiopathic pulmonary fibrosis (special emphasis on isoquinoline alkaloids). Futur J Pharm Sci 2021; 7: 156. [DOI: 10.1186/s43094-021-00304-5]

[147] Lettieri S, Bertuccio FR, Del Frate L, Perrotta F, Corsico AG, et al. The plastic interplay between lung regeneration phenomena and fibrotic evolution: current challenges and novel therapeutic perspectives. Int J Mol Sci 2023; 25(1): 547. [PMID: 38203718 DOI: 10.3390/ijms25010547]

[148] Serna Valverde AL, Reed L, Cuevas Ocaña S, Kiu Lo PC, Tatler A, et al. In vitro modelling of respiratory infections in idiopathic pulmonary fibrosis (IPF) using human induced pluripotent stem cell hiPSCs-derived alveolar epithelial type II cells. ERJ Open Res 2023; 9(suppl 10): 79. [DOI: 10.1183/23120541.LSC-2023.79]

[149] Calthorpe RJ, Poulter C, Smyth AR, Sharkey D, Bhatt J, et al. Complex roles of TGF-β signaling pathways in lung development and bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2023; 324(3): L285-L96. [PMID: 36625900 DOI: 10.1152/ajplung.00106.2021]

[150] Tlatelpa-Romero B, Cázares-Ordoñez V, Oyarzábal LF, Vázquez-de-Lara LG. The role of pulmonary surfactant phospholipids in fibrotic lung diseases. Int J Mol Sci 2022; 24(1): 326. [PMID: 36613771 DOI: 10.3390/ijms24010326]

[151] Conese M, Di Gioia S. Pathophysiology of lung disease and wound repair in cystic fibrosis. Pathophysiology 2021; 28(1): 155-88. [PMID: 35366275 DOI: 10.3390/pathophysiology28010011]

[152] Remex NS, Abdullah CS, Aishwarya R, Nitu SS, Traylor J, et al. Sigmar1 ablation leads to lung pathological changes associated with pulmonary fibrosis, inflammation, and altered surfactant proteins levels. Front Physiol 2023; 14: 1118770. [PMID: 37051024 DOI: 10.3389/fphys.2023.1118770]

[153] Bridges JP, Vladar EK, Kurche JS, Krivoi A, Stancil IT, et al. Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium. J Clin Invest 2025; 135(1): e183836. [PMID: 39744946 DOI: 10.1172/JCI183836]

[154] Di Gioia S, Sardo C, Castellani S, Porsio B, Belgiovine G, et al. From genesis to revelation: the role of inflammatory mediators in chronic respiratory diseases and their control by nucleic acid-based drugs. Curr Drug Deliv 2017; 14(2): 253-71. [PMID: 27557670 DOI: 10.2174/1567201813666160824142843]

[155] Schneider JP, Wrede C, Mühlfeld C. The three-dimensional ultrastructure of the human alveolar epithelium revealed by focused ion beam electron microscopy. Int J Mol Sci 2020; 21(3): 1089. [PMID: 32041332 DOI: 10.3390/ijms21031089]

[156] Ochs M, Knudsen L, Hegermann J, Wrede C, Grothausmann R, et al. Using electron microscopes to look into the lung. Histochem Cell Biol 2016; 146: 695-707. [PMID: 27688057 DOI: 10.1007/s00418-016-1502-z]

[157] Beike L, Wrede C, Hegermann J, Lopez-Rodriguez E, Kloth C, et al. Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the TGF-β1-induced mouse model of pulmonary fibrosis. Lab Invest 2019; 99(6): 830-52. [PMID: 30700849 DOI: 10.1038/s41374-019-0189-x]

[158] Rühl N, Lopez-Rodriguez E, Albert K, Smith BJ, Weaver TE, et al. Surfactant protein B deficiency induced high surface tension: relationship between alveolar micromechanics, alveolar fluid properties and alveolar epithelial cell injury. Int J Mol Sci 2019; 20(17): 4243. [PMID: 31480246 DOI: 10.3390/ijms20174243]

[159] Knudsen L, Hummel B, Wrede C, Zimmermann R, Perlman CE, et al. Acinar micromechanics in health and lung injury: what we have learned from quantitative morphology. Front Physiol 2023; 14: 1142221. [PMID: 37025383 DOI: 10.3389/fphys.2023.1142221]

[160] Öztürk BÇ, Gemicioğlu B. Pathophysiology of the upper and lower airways. In: Cingi C, Yorgancıoğlu A, Bayar Muluk N, Cruz AA, editors. Airway diseases. Cham: Springer; 2023. pp. 1-14.

[161] Sivapalan R. Molecular mechanisms driving alveolarization and their clinical implications: a literature review. Undergrad Res Nat Clin Sci Technol J 2024; 8: 1-8. [DOI: 10.26685/urncst.705]

[162] Vannan A, Lyu R, Williams AL, Negretti NM, Mee ED, et al. Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis. Nat Genet 2025; 57(3): 647-658. [PMID: 39901013 DOI: 10.1038/s41588-025-02080-x]

[163] Schuliga M, Read J, Knight DA. Ageing mechanisms that contribute to tissue remodeling in lung disease. Ageing Res Rev 2021; 70: 101405. [PMID: 34242806 DOI: 10.1016/j.arr.2021.101405]

[164] Vannan A, Lyu R, Williams AL, Negretti NM, Mee ED, et al. Image-based spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis. bioRxiv 2023: 2023.12.15.571954. [PMID: 38168317 DOI: 10.1101/2023.12.15.571954]

[165] Vallejos MAS. Microstructural study of murine lung peranchyma mechanics through the analysis of three-dimensional reconstructions using the μ-Ct technique. Chile: Pontificia Universidad Catolica de Chile; 2021. [DOI: 10.7764/tesisUC/ING/52774]

[166] Liu J, Zhao L, Li C, Jia Y, Yang Z, et al. Mesenchymal stem cell treatment alleviates seawater drowning induced lung injury by inhibiting the TNFα/Snail/EMT pathway. J Thorac Dis 2024; 16(11): 7836-7852. [PMID: 39678856 DOI: 10.21037/jtd-24-1471]

[167] Quiros K, Nelson T, Ulu A, Dominguez E, Nordgren T, et al. Fibrotic and emphysematous murine lung mechanics under negative-pressure ventilation. Am J Physiol Lung Cell Mol Physiol 2025; 328(3): L443-L55. [PMID: 39812236 DOI: 10.1152/ajplung.00087.2024]

[168] Robinson PD. Lung function testing including multiple breath washout. In: Hodson and Geddes’ Cystic Fibrosis. CRC Press; 2023. pp. 497-511.

[169] Liu Q, Guan J, Song R, Zhang X, Mao S. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants. Acta Biomater 2022; 140: 76-87. [PMID: 34843949 DOI: 10.1016/j.actbio.2021.11.034]

[170] Geitner CM, Becher T, Frerichs I, Weiler N, Bates JH, et al. An approach to study recruitment/derecruitment dynamics in a patient-specific computational model of an injured human lung. Int J Numer Method Biomed Eng 2023; 39(9): e3745. [PMID: 37403527 DOI: 10.1002/cnm.3745]

[171] Schiebler ML, Tsuchiya N, Hahn A, Fain S, Denlinger L, et al. Imaging regional airway involvement of asthma: heterogeneity in ventilation, mucus plugs and remodeling. Adv Exp Med Biol 2023; 1426: 163-84. [PMID: 37464121 DOI: 10.1007/978-3-031-32259-4_8]

[172] Klay D, Grutters JC, van der Vis JJ, Platenburg MG, Kelder JC, et al. Progressive disease with low survival in adult patients with pulmonary fibrosis carrying surfactant-related gene mutations: an observational study. Chest 2023; 163(4): 870-80. [PMID: 36370864 DOI: 10.1016/j.chest.2022.11.002]

[173] Da Silva E, Vogel U, Hougaard KS, Pérez-Gil J, Zuo YY, et al. An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function. Curr Res Toxicol 2021; 2: 225-36. [PMID: 34345865 DOI: 10.1016/j.crtox.2021.05.005]

[174] Milad N, Morissette MC. Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure. Eur Respir Rev 2021; 30(162): 210077. [PMID: 34911693 DOI: 10.1183/16000617.0077-2021]

[175] Yoon S-Y, Concepcion NDP, DiPrete O, Vargas SO, Winant AJ, et al. Neonatal and infant lung disorders: glossary, practical approach, and diagnoses. J Thorac Imaging 2024; 39(1): 3-17. [PMID: 37982525 DOI: 10.1097/RTI.0000000000000758]

[176] Tsujioka Y, Nishimura G, Nishi E, Kono T, Nozaki T, et al. Childhood interstitial lung diseases: current understanding of the classification and imaging findings. Jpn J Radiol 2024; 42(9): 937-52. [PMID: 39012450 DOI: 10.1007/s11604-024-01603-6]

[177] Boucherat O, Agrawal V, Lawrie A, Bonnet S. The latest in animal models of pulmonary hypertension and right ventricular failure. Cir Res 2022; 130(9): 1466-86. [PMID: 35482834 DOI: 10.1161/CIRCRESAHA.121.319971]

[178] Passaro F, Tocchetti CG, Spinetti G, Paudice F, Ambrosone L, et al. Targeting fibrosis in the failing heart with nanoparticles. Adv Drug Deliv Rev 2021; 174: 461-81. [PMID: 33984409 DOI: 10.1016/j.addr.2021.05.004]

[179] Kasravi M, Ahmadi A, Babajani A, Mazloomnejad R, Hatamnejad MR, et al. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine. Biomater Res 2023; 27(1): 10. [PMID: 36759929 DOI: 10.1186/s40824-023-00348-z]

[180] Peña OA, Martin P. Cellular and molecular mechanisms of skin wound healing. Nat Rev Mol Cell Biol 2024; 25(8): 599-616. [PMID: 38528155 DOI: 10.1038/s41580-024-00715-1]

[181] Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, et al. The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options. Cancers 2021; 13(17): 4442. [PMID: 34503252 DOI: 10.3390/cancers13174442]

[182] Clemente-Suárez VJ, Martín-Rodríguez A, Redondo-Flórez L, Villanueva-Tobaldo CV, Yáñez-Sepúlveda R, et al. Epithelial transport in disease: an overview of pathophysiology and treatment. Cells 2023; 12(20): 2455. [PMID: 37887299 DOI: 10.3390/cells12202455]

[183] Cartwright IM, Zhou L, Koch SD, Welch N, Zakharov D, et al. Chlorination of epithelial tight junction proteins by neutrophil myeloperoxidase promotes barrier dysfunction and mucosal inflammation. JCI Insight 2024; 9(14): e178525. [PMID: 39133648 DOI: 10.1172/jci.insight.178525]

[184] Fließer E, Lins T, Berg JL, Kolb M, Kwapiszewska G. The endothelium in lung fibrosis: a core signaling hub in disease pathogenesis? Am J Physiol Cell Physiol 2023; 325(1): C2-C16. [PMID: 37184232 DOI: 10.1152/ajpcell.00097.2023]

[185] Kumar V, Xin X, Ma J, Tan C, Osna N, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021; 176: 113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888]

[186] Younesi FS, Miller AE, Barker TH, Rossi FMV, Hinz B. Fibroblast and myofibroblast activation in normal tissue repair and fibrosis. Nat Rev Mol Cell Biol 2024; 25(8): 617-638. [PMID: 38589640 DOI: 10.1038/s41580-024-00716-0]

[187] Tai Y, Woods EL, Dally J, Kong D, Steadman R, et al. Myofibroblasts: function, formation, and scope of molecular therapies for skin fibrosis. Biomolecules 2021; 11(8): 1095. [PMID: 34439762 DOI: 10.3390/biom11081095]

[188] Pot SA, Lin Z, Shiu J, Benn MC, Vogel V. Growth factors and mechano-regulated reciprocal crosstalk with extracellular matrix tune the keratocyte-fibroblast/myofibroblast transition. Sci Rep 2023; 13(1): 11350. [PMID: 37443325 DOI: 10.1038/s41598-023-37776-9]

[189] Yu L, Liu S, Jia S, Xu F. Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies. Biomed Pharmacother 2023; 165: 115049. [PMID: 37364480 DOI: 10.1016/j.biopha.2023.115049]

[190] Gangavarapu A, Tapia-Lopez LV, Sarkar B, Pena-Zacarias J, Badruddoza AZM, et al. Lipid nanoparticles for enhancing oral bioavailability. Nanoscale 2024; 16(39): 18319-38. [PMID: 39291697 DOI: 10.1039/d4nr01487a]

[191] Ashfaq R, Rasul A, Asghar S, Kovács A, Berkó S, et al. Lipid nanoparticles: an effective tool to improve the bioavailability of nutraceuticals. Int J Mol Sci 2023; 24(21): 15764. [PMID: 37958750 DOI: 10.3390/ijms242115764]

[192] Bai X, Chen Q, Li F, Teng Y, Tang M, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat Commun 2024; 15(1): 6844. [PMID: 39122711 DOI: 10.1038/s41467-024-51056-8]

[193] Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnology 2022; 20(1): 276. [PMID: 35701851 DOI: 10.1186/s12951-022-01478-7]

[194] Chen J, Cong X. Surface-engineered nanoparticles in cancer immune response and immunotherapy: current status and future prospects. Biomed Pharmacother 2023; 157: 113998. [PMID: 36399829 DOI: 10.1016/j.biopha.2022.113998]

[195] Auger M, Sorroza-Martinez L, Brahiti N, Huppé C-A, Faucher-Giguère L, et al. Enhancing peptide and PMO delivery to mouse airway epithelia by chemical conjugation with the amphiphilic peptide S10. Mol Ther Nucleic Acids 2024; 35(3): 102290. [PMID: 39233851 DOI: 10.1016/j.omtn.2024.102290]

[196] Doxakis E. Therapeutic antisense oligonucleotides for movement disorders. Med Res Rev 2021; 41(5): 2656-88. [PMID: 32656818 DOI: 10.1002/med.21706]

[197] Hou M, Wu X, Zhao Z, Deng Q, Chen Y, et al. Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury. Acta Biomater 2022; 143: 344-55. [PMID: 35189380 DOI: 10.1016/j.actbio.2022.02.018]

[198] Deng Z, Liu S. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases. Drug Deliv Transl Res 2021; 11: 1475-97. [PMID: 33860447 DOI: 10.1007/s13346-021-00977-8]

[199] Hasan N, Imran M, Jain D, Jha SK, Nadaf A, et al. Advanced targeted drug delivery by bioengineered white blood cell-membrane camouflaged nanoparticulate delivery nanostructures. Environ Res 2023; 238(Pt 1): 117007. [PMID: 37689337 DOI: 10.1016/j.envres.2023.117007]

[200] Fernandes NB, Nayak Y, Garg S, Nayak UY. Multifunctional engineered mesoporous silica/inorganic material hybrid nanoparticles: theranostic perspectives. Coord Chem Rev 2023; 478: 214977. [DOI: 10.1016/j.ccr.2022.214977]

[201] Zeng C, Yue H, Wang C, Ju X, Wang T, et al. Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis. J Transl Med 2024; 22(1): 910. [PMID: 39375691 DOI: 10.1186/s12967-024-05655-0]

[202] Gaytan SL, Beaven E, Gadad SS, Nurunnabi M. Progress and prospect of nanotechnology for cardiac fibrosis treatment. Interdiscip Med 2023; 1(4): e20230018. [PMID: 38089921 DOI: 10.1002/INMD.20230018]

[203] Jin C, Xue L, Zhang L, Yu L, Wu P, et al. Engineered nanoparticles for theranostic applications in kidney repair. Adv Healthc Mater 2025; 14(1): e2402480. [PMID: 39617999 DOI: 10.1002/adhm.202402480]

[204] Harun-Ur-Rashid M, Jahan I, Foyez T, Imran AB. Bio-inspired nanomaterials for micro/nanodevices: a new era in biomedical applications. Micromachines 2023; 14(9): 1786. [PMID: 37763949 DOI: 10.3390/mi14091786]

[205] Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, et al. Delphi consensus recommendations on management of dosing, adverse events, and comorbidities in the treatment of idiopathic pulmonary fibrosis with nintedanib. Clin Med Insights Circ Respir Pulm Med 2021; 15: 11795484211006050. [PMID: 33854398 DOI: 10.1177/11795484211006050]

[206] Liu Y, Qu Y, Yang Y, Deng Q, Luo Y, et al. Algae-based flexible localized oxygen control around cells: an approach leading to more biomimetic microphysiological systems. Chem Eng J 2024; 502: 158040. [DOI: 10.1016/j.cej.2024.158040]

[207] Ibrahim JP, Butcher NJ, Kothapalli A, Subasic CN, Blanchfield JT, et al. Utilization of endogenous albumin trafficking pathways in the lungs has potential to modestly increase the lung interstitial access and absorption of drug delivery systems after inhaled administration. Expert Opin Drug Deliv 2023; 20(8): 1145-55. [PMID: 37535434 DOI: 10.1080/17425247.2023.2244881]

[208] Li R, Jia Y, Kong X, Nie Y, Deng Y, et al. Novel drug delivery systems and disease models for pulmonary fibrosis. J Control Release 2022; 348: 95-114. [PMID: 35636615 DOI: 10.1016/j.jconrel.2022.05.039]

[209] Maaz A, Blagbrough IS, De Bank PA. A cell-based nasal model for screening the deposition, biocompatibility, and transport of aerosolized PLGA nanoparticles. Mol Pharm 2024; 21(3): 1108-24. [PMID: 38333983 DOI: 10.1021/acs.molpharmaceut.3c00639]

[210] Sabuj MZR, Islam N. Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections. Nanoscale Adv 2021; 3(14): 4005-18. [PMID: 36132845 DOI: 10.1039/d1na00205h]

[211] Peña Q, Wang A, Zaremba O, Shi Y, Scheeren HW, et al. Metallodrugs in cancer nanomedicine. Chem Soc Rev 2022; 51(7): 2544-82. [DOI: 10.1039/D1CS00468A]

[212] Cabral H, Li J, Miyata K, Kataoka K. Controlling the biodistribution and clearance of nanomedicines. Nat Rev Bioeng 2024; 2(3): 214-32. [DOI: 10.1038/s44222-023-00138-1]

[213] Xun Z, Li T, Xue X. The application strategy of liposomes in organ targeting therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2024; 16(2): e1955. [PMID: 38613219 DOI: 10.1002/wnan.1955]

[214] Guo D, Huang Y, Jin X, Zhang C, Zhu X. A redox-responsive, in-situ polymerized polyplatinum(IV)-coated gold nanorod as an amplifier of tumor accumulation for enhanced thermo-chemotherapy. Biomaterials 2021; 266: 120400. [PMID: 33022477 DOI: 10.1016/j.biomaterials.2020.120400]

[215] Bianchi L, Mooney R, Cornejo YR, Schena E, Berlin JM, et al. Thermal analysis of laser irradiation-gold nanorod combinations at 808 nm, 940 nm, 975 nm and 1064 nm wavelengths in breast cancer model. Int J Hyperthermia 2021; 38(1): 1099-110. [PMID: 34315306 DOI: 10.1080/02656736.2021.1956601]

[216] Mousavi SM, Hashemi SA, Mazraedoost S, Yousefi K, Gholami A, et al. Multifunctional gold nanorod for therapeutic applications and pharmaceutical delivery considering cellular metabolic responses, oxidative stress and cellular longevity. Nanomaterials 2021; 11(7): 1868. [PMID: 34361251 DOI: 10.3390/nano11071868]

[217] De Lombaerde E, De Wever O, De Geest BG. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim Biophys Acta Rev Cancer 2021; 1875(2): 188526. [PMID: 33617921 DOI: 10.1016/j.bbcan.2021.188526]

[218] Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, et al. Targeted drug delivery strategies for precision medicines. Nat Rev Mater 2021; 6(4): 351-70. [PMID: 34950512 DOI: 10.1038/s41578-020-00269-6]

[219] Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev 2021; 178: 113971. [PMID: 34530013 DOI: 10.1016/j.addr.2021.113971]

[220] Gerini G, Traversa A, Cece F, Cassandri M, Pontecorvi P, et al. Deciphering the transcriptional metabolic profile of adipose-derived stem cells during osteogenic differentiation and epigenetic drug treatment. Cells 2025; 14(2): 135. [PMID: 39851564 DOI: 10.3390/cells14020135]

[221] Gulhane AV, Chen DL. Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases. Br J Radiol 2022; 95(1132): 20210824. [PMID: 34752146 DOI: 10.1259/bjr.20210824]

[222] Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, et al. Ratio of FEV₁/slow vital capacity of < 0.7 is associated with clinical, functional, and radiologic features of obstructive lung disease in smokers with preserved lung function. Chest 2021; 160(1): 94-103. [PMID: 33539837 DOI: 10.1016/j.chest.2021.01.067]

[223] Diwan R, Bhatt HN, Beaven E, Nurunnabi M. Emerging delivery approaches for targeted pulmonary fibrosis treatment. Adv Drug Deliv Rev 2024; 204: 115147. [PMID: 38065244 DOI: 10.1016/j.addr.2023.115147]

[224] Thong L, McElduff EJ, Henry MT. Trials and treatments: an update on pharmacotherapy for idiopathic pulmonary fibrosis. Life 2023; 13(2): 486. [PMID: 36836843 DOI: 10.3390/life13020486]

[225] Sofia C, Comes A, Sgalla G, Richeldi L . Promising advances in treatments for the management of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 2024; 25(6): 717- 25. [PMID: 38832823 DOI: 10.1080/14656566.2024.2354460]

[226] Pandey V, Haider T, Sharma R, Akram W, Soni ML, et al. Fundamentals of targeted drug delivery. In: Yadav AK, Jain K, editors. Novel carrier systems for targeted and controlled drug delivery. Singapore: Springer; 2024. pp. 251-71.

[227] Fu Q, Liu Y, Peng C, Muluh TA, Anayyat U, et al. Recent advancement in inhaled nano-drug delivery for pulmonary, nasal, and nose-to-brain diseases. Curr Drug Deliv 2025; 22(1): 3-14. [PMID: 38275044 DOI: 10.2174/0115672018268047231207105652]

[228] Li C, Naveed M, Dar K, Liu Z, Baig MMFA, et al. Therapeutic advances in cardiac targeted drug delivery: from theory to practice. J Drug Target 2021; 29(3): 235-48. [PMID: 32933319 DOI: 10.1080/1061186X.2020.1818761]

[229] Bhattacharya M, Ramachandran P. Immunology of human fibrosis. Nat Immunol 2023; 24(9): 1423-33. [PMID: 37474654 DOI: 10.1038/s41590-023-01551-9]

[230] Bowers SLK, Meng Q, Molkentin JD. Fibroblasts orchestrate cellular crosstalk in the heart through the ECM. Nat Cardiovasc Res 2022; 1(4): 312-21. [PMID: 38765890 DOI: 10.1038/s44161-022-00043-7]

[231] Conte E. Targeting monocytes/macrophages in fibrosis and cancer diseases: therapeutic approaches. Pharmacol Ther 2022; 234: 108031. [PMID: 34774879 DOI: 10.1016/j.pharmthera.2021.108031]

[232] Gauthier V, Kyriazi M, Nefla M, Pucino V, Raza K, et al. Fibroblast heterogeneity: keystone of tissue homeostasis and pathology in inflammation and ageing. Front Immunol 2023; 14: 1137659. [PMID: 36926329 DOI: 10.3389/fimmu.2023.1137659]

[233] Vallariello E. Regulation of Pancreatic Cancer Fibrosis by a TFEB-mediated Transcriptional Program 2021.

[234] Schupp J. A humanized mouse melanoma model for liposomal drug delivery: Dissertation. Mainz, Johannes Gutenberg-Universität Mainz, 2022; 2021.

[235] Sisto M, Ribatti D, Lisi S. Organ fibrosis and autoimmunity: the role of inflammation in TGFβ-dependent EMT. Biomolecules 2021; 11(2): 310. [PMID: 33670735 DOI: 10.3390/biom11020310]

[236] Aftabi S, Barzegar Behrooz A, Cordani M, Rahiman N, Sadeghdoust M, et al. Therapeutic targeting of TGF-β in lung cancer. FEBS J 2024. [PMID: 39083441 DOI: 10.1111/febs.17234]

[237] Sisto M, Ribatti D, Lisi S. ADAM 17 and epithelial-to-mesenchymal transition: the evolving story and its link to fibrosis and cancer. J Clin Med 2021; 10(15): 3373. [PMID: 34362154 DOI: 10.3390/jcm10153373]

[238] Han X, Gong N, Xue L, Billingsley MM, El-Mayta R, et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat Commun 2023; 14(1): 75. [PMID: 36650129 DOI: 10.1038/s41467-022-35637-z]

[239] Ogunmokun G, Dewanjee S, Chakraborty P, Valupadas C, Chaudhary A, et al. The potential role of cytokines and growth factors in the pathogenesis of Alzheimer’s disease. Cells 2021; 10(10): 2790. [PMID: 34685770 DOI: 10.3390/cells10102790]

[240] Jia G, Jiang Y, Li X. Targeted drug conjugates in cancer therapy: challenges and opportunities. Pharm Sci Adv 2024; 2: 100048. [DOI: 10.1016/j.pscia.2024.100048]

[241] Lin G, Zhang M. Ligand chemistry in anti-tumor theranostic nanoparticles. Acc Chem Res 2023; 56(12): 1578-90. [PMID: 37220248 DOI: 10.1021/acs.accounts.3c00151]

[242] Grey EL. Polymeric microparticles and stimuli-responsive hydrogels targeting macrophages. US: University of Colorado at Boulder; 2024.

[243] Yu Q, Zhang Q, Wu Z, Yang Y. Inhalable metal-organic frameworks: a promising delivery platform for pulmonary diseases treatment. ACS Nano 2025; 19(3): 3037-53. [PMID: 39808505 DOI: 10.1021/acsnano.4c16873]

[244] Zheng R, Yu C, Yao D, Cai M, Zhang L, et al. Engineering stimuli-responsive materials for precision medicine. Small 2025; 21(1): 2406439. [PMID: 39444066 DOI: 10.1002/smll.202406439]

[245] Toutounchian S, Ahmadbeigi N, Mansouri V. Retinal and choroidal neovascularization antivascular endothelial growth factor treatments: the role of gene therapy. J Ocul Pharmacol Ther 2022; 38(8): 529-48. [PMID: 36125411 DOI: 10.1089/jop.2022.0022]

[246] Evangelista-Leite D, Carreira ACO, Nishiyama MY, Gilpin SE, Miglino MA . The molecular mechanisms of extracellular matrix-derived hydrogel therapy in idiopathic pulmonary fibrosis models. Biomaterials 2023; 302: 122338. [PMID: 37820517 DOI: 10.1016/j.biomaterials.2023.122338]

[247] Li XN, Lin YP, Han MM, Fang YF, Xing L, et al. Modulating fibrotic mechanical microenvironment for idiopathic pulmonary fibrosis therapy. Adv Mater 2024; 36(50): e2407661. [PMID: 39529565 DOI: 10.1002/adma.202407661]

[248] Khalili L, Dehghan G, Sheibani N, Khataee A. Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: recent advances and challenges. Int J Biol Macromol 2022; 213: 166-94. [PMID: 35644315 DOI: 10.1016/j.ijbiomac.2022.05.156]

[249] Ashok B, Peppas NA, Wechsler ME. Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9. J Drug Deliv Sci Technol 2021; 65: 102728. [PMID: 34335878 DOI: 10.1016/j.jddst.2021.102728]

[250] Liu Q, Zhang X, Xue J, Chai J, Qin L, et al. Exploring the intrinsic micro-/nanoparticle size on their in vivo fate after lung delivery. J Control Release 2022; 347: 435-48. [PMID: 35537539 DOI: 10.1016/j.jconrel.2022.05.006]

[251] Yan X, Sha X. Nanoparticle-mediated strategies for enhanced drug penetration and retention in the airway mucosa. Pharmaceutics 2023; 15(10): 2457. [PMID: 37896217 DOI: 10.3390/pharmaceutics15102457]

[252] Ibrahim M, Ramadan E, Elsadek NE, Emam SE, Shimizu T, et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Control Release 2022; 351: 215-30. [PMID: 36165835 DOI: 10.1016/j.jconrel.2022.09.031]

[253] Georgakopoulou VE, Papalexis P, Trakas N. Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections. J Biol Methods 2024; 11(4): e99010032. [PMID: 39839091 DOI: 10.14440/jbm.2024.0065]

[254] Dhege CT, Kumar P, Choonara YE. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS). Int J Pharm 2024; 657: 124182. [PMID: 38697584 DOI: 10.1016/j.ijpharm.2024.124182]

[255] Wong SL, Gan JS, De Rubis G, Paudel KR, Yeung S, et al. Innovative phytoceutical-based drug delivery in the management of pulmonary fibrosis: a roadmap towards inhaled therapeutics. J Drug Deliv Sci Technol 2024; 99: 105942. [DOI: 10.1016/j.jddst.2024.105942]

[256] Kumar M, Hilles AR, Almurisi SH, Bhatia A, Mahmood S. Micro and nano-carriers-based pulmonary drug delivery system: their current updates, challenges, and limitations - a review. JCIS Open 2023; 12: 100095. [DOI: 10.1016/j.jciso.2023.100095]

[257] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20(2): 101-24. [PMID: 33277608 DOI: 10.1038/s41573-020-0090-8]

[258] Gamal O, Agamey AT, Amr Z, El-Sherbiny IM . Revolutionizing lung cancer treatment with smart pulmonary drug delivery nanosystems. J Drug Deliv Sci Technol 2024; 101: 106158. [DOI: 10.1016/j.jddst.2024.106158]

[259] Paramshetti S, Angolkar M, Talath S, Osmani RAM, Spandana A, et al. Unravelling the in vivo dynamics of liposomes: insights into biodistribution and cellular membrane interactions. Life Sci 2024; 346: 122616. [PMID: 38599316 DOI: 10.1016/j.lfs.2024.122616]

[260] Feng X, Shi Y, Zhang Y, Lei F, Ren R, et al. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases: a review. Int J Nanomedicine 2024; 19: 1509-38. [PMID: 38384321 DOI: 10.2147/IJN.S446919]

[261] Anjum MM, Patel KK, Bhattacharya S, Arya DK, Pandey P, et al. Overcoming barriers in cystic fibrosis therapy through inhalational lipid nanoparticles: challenges and advances. J Drug Deliv Sci Technol 2023; 89: 105068. [DOI: 10.1016/j.jddst.2023.105068]

[262] Li J, Xiao Y, Zhang Y, Li S, Zhao M, et al. Pulmonary delivery of specialized pro-resolving mediators-based nanotherapeutics attenuates pulmonary fibrosis in preclinical animal models. ACS Nano 2023; 17(16): 15354-70. [PMID: 37535431 DOI: 10.1021/acsnano.2c10388]

[263] Fatehi Hassanabad A, Zarzycki AN, Fedak PW . Cellular and molecular mechanisms driving cardiac tissue fibrosis: on the precipice of personalized and precision medicine. Cardiovasc Pathol 2024; 71: 107635. [PMID: 38508436 DOI: 10.1016/j.carpath.2024.107635]

[264] Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, et al. Precision medicine and the future of cardiovascular diseases: a clinically oriented comprehensive review. J Clin Med 2023; 12(5): 1799. [PMID: 36902588 DOI: 10.3390/jcm12051799]

[265] Waheed S, Li Z, Zhang F, Chiarini A, Armato U, et al. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 2022; 20(1): 395. [PMID: 36045386 DOI: 10.1186/s12951-022-01605-4]

[266] Ibrahim HK. From nanotech to AI: the cutting-edge technologies shaping the future of medicine. African J Adv Pure Appl Sci (AJAPAS) 2024: 410-27.

[267] Wang J, Zhang H, Wan W, Yang H, Zhao J. Advances in nanotechnological approaches for the detection of early markers associated with severe cardiac ailments. Nanomedicine 2024; 19(16): 1487-506. [PMID: 39121377 DOI: 10.1080/17435889.2024.2364581]

[268] AbouSamra MM. Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications. J Liposome Res 2024; 34(4): 728-43. [PMID: 38988127 DOI: 10.1080/08982104.2024.2377085]

[269] Hye T, Moinuddin SM, Sarkar T, Nguyen T, Saha D, et al. An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opin Drug Deliv 2023; 20(3): 335-48. [PMID: 36720629 DOI: 10.1080/17425247.2023.2175814]

[270] Siafaka PI, Bülbül EÖ, Miliotou AN, Karantas ID, Okur ME, et al. Nano-based carriers for pulmonary drug delivery: a review on the available drug delivery applications and toxicity issues. J Drug Deliv Sci Technol 2024; 92(1): 105381. [DOI: 10.1016/j.jddst.2024.105381]

[271] Duraloglu C, Baysal I, Yabanoglu-Ciftci S, Arica B. Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation. Drug Dev Ind Pharm 2024; 50(7): 671-86. [PMID: 39099436 DOI: 10.1080/03639045.2024.2387166]

[272] Shariatinia Z. Big family of nano- and microscale drug delivery systems ranging from inorganic materials to polymeric and stimuli-responsive carriers as well as drug-conjugates. J Drug Deliv Sci Technol 2021; 66: 102790. [DOI: 10.1016/j.jddst.2021.102790]

[273] Fatima M, Almalki WH, Khan T, Sahebkar A, Kesharwani P. Harnessing the power of stimuli-responsive nanoparticles as an effective therapeutic drug delivery system. Adv Mater 2024; 36(24): e2312939. [PMID: 38447161 DOI: 10.1002/adma.202312939]

[274] Wang Z, Wang X, Xu W, Li Y, Lai R, et al. Translational challenges and prospective solutions in the implementation of biomimetic delivery systems. Pharmaceutics 2023; 15(11): 2623. [PMID: 38004601 DOI: 10.3390/pharmaceutics15112623]

[275] Lattanzi W, Ripoli C, Greco V, Barba M, Iavarone F, et al. Basic and preclinical research for personalized medicine. J Pers Med 2021; 11(5): 354. [PMID: 33946634 DOI: 10.3390/jpm11050354]

[276] Amekyeh H, Tarlochan F, Billa N. Practicality of 3D printed personalized medicines in therapeutics. Front Pharmacol 2021; 12: 646836. [PMID: 33912058 DOI: 10.3389/fphar.2021.646836]

[277] Furukawa H, Oka S, Higuchi T, Shimada K, Hashimoto A, et al. Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021; 13: 1759720X211022506. [PMID: 34211592 DOI: 10.1177/1759720X211022506]

[278] Muruganandam M, Ariza-Hutchinson A, Patel RA, Sibbitt Jr WL. Biomarkers in the pathogenesis, diagnosis, and treatment of systemic sclerosis. J flamm Res 2023: 4633-60. [PMID: 37868834 DOI: 10.2147/JIR.S379815]

[279] Li J, Zou Y, Kantapan J, Su H, Wang L, et al. TGF-β/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives. Mol Med Rep 2024; 30(2): 143. [PMID: 38904198 DOI: 10.3892/mmr.2024.13267]

[280] Suhag D, Kaushik S, Taxak VB. Theranostics: combining diagnosis and therapy. In: Handbook of biomaterials for medical applications. Volume 1. Springer; 2024. pp. 271-95. [DOI: 10.1007/978-981-97-4818-1_10]

[281] Li H, Luo Q, Zhang H, Ma X, Gu Z, et al. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem Soc Rev 2023; 52(1): 47-96. [DOI: 10.1039/D2CS00437B]

[282] Ubanako P, Mirza S, Ruff P, Penny C. Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges. Front Mol Biosci 2024; 11: 1447953. [PMID: 39355533 DOI: 10.3389/fmolb.2024.1447953]

[283] Ribeiro J, Lopes I, Gomes AC. A new perspective for the treatment of Alzheimer’s disease: exosome-like liposomes to deliver natural compounds and RNA therapies. Molecules 2023; 28(16): 6015. [PMID: 37630268 DOI: 10.3390/molecules28166015]

[284] Dowaidar M. Drug delivery based exosomes uptake pathways. Neurochem Int 2024; 179: 105835. [PMID: 39147203 DOI: 10.1016/j.neuint.2024.105835]

[285] Nowak-Jary J, Machnicka B . In vivo biodistribution and clearance of magnetic iron oxide nanoparticles for medical applications. Int J Nanomedicine 2023; 18: 4067-100. [PMID: 37525695 DOI: 10.2147/IJN.S415063]

[286] Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, et al. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers 2022; 14(13): 2601. [PMID: 35808648 DOI: 10.3390/polym14132601]

[287] Shinde A, Illath K, Gupta P, Shinde P, Lim KT, et al. A review of single-cell adhesion force kinetics and applications. Cells 2021; 10(3): 577. [PMID: 33808043 DOI: 10.3390/cells10030577]

[288] Jahromi LP, Shahbazi MA, Maleki A, Azadi A, Santos HA. Chemically engineered immune cell-derived microrobots and biomimetic nanoparticles: emerging biodiagnostic and therapeutic tools. Adv Sci 2021; 8(8): 2002499. [PMID: 33898169 DOI: 10.1002/advs.202002499]

[289] Guan X, Xing S, Liu Y. Engineered cell membrane-camouflaged nanomaterials for biomedical applications. Nanomaterials 2024; 14(5): 413. [PMID: 38470744 DOI: 10.3390/nano14050413]

[290] Zhang M, Cheng S, Jin Y, Zhang N, Wang Y. Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics. Clin Transl Med 2021; 11(2): e292. [PMID: 33635002 DOI: 10.1002/ctm2.292]

[291] Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov 2021; 11(4): 900-15. [PMID: 33811123 DOI: 10.1158/2159-8290.CD-21-0090]

[292] de Jong J, Cutcutache I, Page M, Elmoufti S, Dilley C, et al. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain 2021; 144(6): 1738-50. [PMID: 33734308 DOI: 10.1093/brain/awab108]

[293] Chauhan N, Chauhan A, Jain S. Advancements in nanomedicine for neurodegenerative diseases: a comprehensive review. TechRxiv 2024. [DOI: 10.22541/au.172983606.69080943/v1]

[294] Rajapaksha W, Khetan R, Johnson IR, Blencowe A, Garg S, et al. Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment. Front Drug Deliv 2024; 4: 1339936. [DOI: 10.3389/fddev.2024.1339936]

[295] Kurtais Aytür Y, Füsun Köseoglu B, Özyemisci Taşkıran Ö, Kutay Ordu Gökkaya N, Ünsal Delialioğlu S, et al. Pulmonary rehabilitation principles in SARS-COV-2 infection (COVID-19): the revised guideline for the acute, subacute, and post-COVID-19 rehabilitation. Turk J Phys Med Rehabil 2021; 67(2): 129-145. [PMID: 34396064 DOI: 10.5606/tftrd.2021.8821]

[296] Han Y, Jiang M, He R, Lv X, Liao X, et al. Mefunidone ameliorates bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol 2021; 12: 713572. [PMID: 34630088 DOI: 10.3389/fphar.2021.713572]

[297] Niazi SK. The future of pharmaceuticals: a nonlinear analysis. Boca Raton: CRC Press; 2022.

[298] Zhao Y, Yan Z, Liu Y, Zhang Y, Shi J, et al. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Stem Cell Res Ther 2021; 12(1): 470. [DOI: 10.1186/s13287-021-02551-y]

[299] Margaria JP, Moretta L, Alves-Filho JC, Hirsch E. PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury. Biomedicines 2022; 10(4): 756. [PMID: 35453505 DOI: 10.3390/biomedicines10040756]